Previous 10 | Next 10 |
CytomX Therapeutics ( NASDAQ: CTMX ) on Wednesday announced strategic actions that are expected to extend the company's cash runway into 2025, including a reduction in its workforce by about 40%. CTMX said it would focus its internal efforts on its wholly-owned therapies, ...
- Company to focus internal efforts on wholly-owned next-generation conditionally activated therapeutics, including IFN alpha-2b cytokine and EpCAM-directed ADC, INDs planned for 2023 - - Partnered clinical-stage programs continue to advance: Phase 2 programs, BMS-986249 (anti-C...
Analyst comments provided a significant catalyst for midday trading on Thursday. Otis Worldwide ( NYSE: OTIS ) and Boston Beer ( SAM ) both lost ground on separate downgrades. Elsewhere in the market, CytomX Therapeutics ( CTMX ) shed almost a third of its value followin...
Gainers: Grove Collaborative ( GROV ) +80% . Faraday Future Intelligent Electric ( FFIE ) +30% . Bed Bath & Beyond ( BBBY ) +27% . Dakota Gold ( DC ) +21% . Bolt Biotherapeutics ( BOLT ) +20% . Miromatrix Medical ( MIRO...
Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...
Several Street firms have downgraded CytomX Therapeutics ( NASDAQ: CTMX ) after the company released disappointing phase 2 results on praluzatamab ravtansine for breast cancer Wednesday. Shares are down 26% in Thursday premarket trading. CytomX ( CTMX ) sai...
DiaMedica Therapeutics ( DMAC ) -35% after FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold . CytomX Therapeutics ( CTMX ) -27% on phase 2 study of breast cancer antibody praluzatamab . Yatsen Holding ( YSG ) -1...
CytomX Therapeutics ( NASDAQ: CTMX ) on Wednesday said its phase 2 trial of its antibody praluzatamab ravtansine in breast cancer patients met the main goal of the study. CTMX said the study met the primary endpoint of objective response rate of greater than 10% i...
- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer - - Secondary endpoints including clinical benefit rate at 24 weeks and median progression-free survival were 40 percent and 2.6 months, respectively - - Arm B did not pass ...
Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...